Mirum Pharmaceuticals raises 2026 net product sales outlook

Mirum Pharmaceuticals

06/05/2026 21:18

Overview

Rare disease drugmaker's Q1 net product sales rose 43% yr/yr to $159.9 mln

Company raised 2026 net product sales guidance to $660-$680 mln

Q1 net loss widened sharply due to $726.3 mln non-recurring R&D expense

Outlook

Mirum Pharmaceuticals raises 2026 net product sales guidance to $660-$680 mln

Company expects NDA submission for volixibat in H2 2026

FDA Priority Review for zilurgisertib with PDUFA date of September 26, 2026

Result Drivers

LIVMARLI SALES GROWTH - Q1 LIVMARLI net product sales rose 55% yr/yr to $113.8 mln, driven by increased demand in rare cholestatic liver diseases

BILE ACID MEDICINES - Q1 net product sales for bile acid medicines rose 20% yr/yr to $46.1 mln

NON-RECURRING R&D EXPENSE - Q1 operating expenses included $726.3 mln in non-recurring in-process R&D expense from Bluejay Therapeutics acquisition

Company press release: ID:nBw6myc76a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Sales
$159.88 mln
Q1 EPS
-$13.43
Q1 Net Income
-$790.16 mln
Q1 Operating Expenses
$949.35 mln
Q1 Operating Income
-$789.47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $140.00, about 32.3% above its May 5 closing price of $105.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)